March 2023 | Boston, USA
Menu
Each has broad utility in multiple fields, and is used to identify structural abnormalities of varying sizes in metaphase or interphase cells. From the de novo discovery of large rearrangements, to specific targets as small as 5kb, the versatility of dGH provides researchers with structural genomic insight at almost any level.
dGH has been adopted in fields ranging from gene editing to biodosimetry. Our current customers include top US gene editing therapy companies, Top 20 Global Pharma companies, specialty biopharmas, and a number of institutional researchers with varied interests. We are interested in discussing partnerships and funding opportunities focused on cellular engineering, dGH assay development, structural biomarker screening and target discovery, undiagnosed diseases, and non-therapeutic areas of gene editing.”
We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.